Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from SkinBioTherapeutics ( (GB:SBTX) ) is now available.
SkinBioTherapeutics said trading in its shares on London’s AIM has been suspended from 7.30 a.m. after it failed to publish interim results for the six months to 31 December 2025 by the 31 March deadline required under market rules. The board attributed the delay to an ongoing internal investigation and an independent forensic review by FRP Advisory, which it expects to complete later in April.
The company anticipates that trading will resume once the outstanding interim results are released and has pledged to update shareholders on the findings of both the review and the board’s probe. The situation introduces uncertainty for investors in the near term, but the conclusion of the forensic work is likely to be pivotal for restoring market confidence in SkinBioTherapeutics’ governance and disclosure practices.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £9.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on SBTX Stock
According to Spark, TipRanks’ AI Analyst, SBTX is a Neutral.
The score is held back primarily by ongoing unprofitability and weak cash flows, despite strong revenue growth and a relatively conservative balance sheet. Technicals also remain bearish with the stock trading below major moving averages and negative MACD, while valuation is constrained by losses (negative P/E) and no dividend yield support.
To see Spark’s full report on SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix platform developed with the University of Manchester. Its core business targets the skin healthcare market through five pillars, led by cosmetic skincare products branded via Croda as Zenakine and AxisBiotix food supplements sold online and through selected Superdrug stores.
The group is also pursuing a consolidation strategy by acquiring complementary skincare and cosmetic businesses that add distribution, geographic reach, and manufacturing capacity. Listed on AIM since 2017 and headquartered in Newcastle, the company aims to funnel its in-house pillar products through these expanded commercial and operational channels.
Average Trading Volume: 4,691,212
Technical Sentiment Signal: Sell
Current Market Cap: £26.56M
For a thorough assessment of SBTX stock, go to TipRanks’ Stock Analysis page.